Novo Nordisk's 7.2 mg dose of Wegovy will compete against Lilly's GLP-1 injection. ...

• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down?The approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program.The newly approved Wegovy HD (semaglutide) injection 7.2 mg is for patients who have already tolerated the currently approved 2.4 mg dose and require additional weight reduction.The therapy is intended to be used alongside a reduced-calorie diet and increased physical activity.Clinical Data From STEP UP Trial Supports ApprovalT ...

Core Insights - The Danish drugmaker received accelerated approval for a new treatment based on the results of its Step Up trial, which demonstrated a mean weight loss of 20.7% for participants with obesity [1] Company Summary - The accelerated approval indicates a significant advancement in the company's product pipeline, potentially enhancing its market position in the obesity treatment sector [1] Industry Summary - The results from the Step Up trial highlight the growing focus on effective obesity treatments within the pharmaceutical industry, reflecting an increasing demand for innovative solutions to address obesity-related health issues [1]

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival Eli Lilly. Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly's obesity drug Z ...

Novo Nordisk won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to that of rival Eli Lilly's competing shot Zepbound https://t.co/pUCnYjWVYd ...

FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile Accessibility StatementSkip Navigation PLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in adults with obesity in the STEP UP trial.1,2 Wegovy® HD ...

US FDA approves higher dose of Novo's Wegovy | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Wegovy lie beside a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab Companies Novo Nordisk A/S Follow U.S. Food and Drug Administration Follow The approval was based on results that showed patients who were given the 7.2 mg dose o ...

Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trialFirst US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health prioritiesWegovy® HD complements Wegovy® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reductionNovo Nordisk expects to launch Wegovy® HD in the US in April 2026 ...

整理 | GLP1减重宝典内容团队 2026年3月，诺和诺德宣布，蔡琰博士正式接任大中国区总裁，肩负起领导中国区业务的重任。作为全球领先的制药公司之一，诺和诺 德的中国市场无疑是其全球战略的重要组成部分，而此次蔡琰的升任，也标志着公司在中国市场深耕已久的进一步深化。蔡琰博士的职 业生涯，不仅见证了诺和诺德在中国的成长，也亲历了全球制药行业的发展变化。她的任命背景、过往履历以及未来展望，反映出诺和 诺德在中国市场的雄心和决心。 ▍ 从东北到全球：医学背景成就跨国高管之路 蔡琰博士出生在中国东北的辽宁大连，在西安成长。她本科毕业于中山医科大学，随后赴澳大利亚接受临床培训，并最终赴丹麦攻读博 士学位，开启了她的全球化职业旅程。这个背景为她日后的职业生涯奠定了坚实的基础：她不仅拥有深厚的医学知识，还具备全球视 野，这使得她能够在跨国制药企业中迅速崭露头角。 在2021年至2024年期间，蔡琰担任临床、医学与注册事务高级副总裁，并于2025年升任为医学与市场事务高级副总裁。她的职业生涯逐 步迈向诺和诺德的全球领导层，成为了公司在全球战略布局中不可或缺的一员。2026年1月，蔡琰被任命为国际运营部市场、医学与注 册事务 ...

Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's (NOVOb.CO), opens new tabpatent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an over ...